Reducing abuse liability of GABAA/benzodiazepine ligands via selective partial agonist efficacy at alpha1 and alpha2/3 subtypes.
about
Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective GABA(A) Receptor Modulators?GABAA receptor subtypes: Therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism.Allosteric modulation of GABA(A) receptor subtypes:effects on visual recognition and visuospatial working memory in rhesus monkeys [corrected].Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes.Neural basis of benzodiazepine reward: requirement for α2 containing GABAA receptors in the nucleus accumbens.Hooked on benzodiazepines: GABAA receptor subtypes and addiction.GABA(A) receptor α subunits differentially contribute to diazepam tolerance after chronic treatment.Intravenous self-administration of γ-hydroxybutyrate (GHB) in baboonsAntagonism of triazolam self-administration in rhesus monkeys responding under a progressive-ratio schedule: In vivo apparent pA2 analysis.Search for α3β₂/₃γ2 subtype selective ligands that are stable on human liver microsomesAssessment of subunit-dependent direct gating and allosteric modulatory effects of carisoprodol at GABA(A) receptors.HZ166, a novel GABAA receptor subtype-selective benzodiazepine site ligand, is antihyperalgesic in mouse models of inflammatory and neuropathic painReinforcing effects of compounds lacking intrinsic efficacy at α1 subunit-containing GABAA receptor subtypes in midazolam- but not cocaine-experienced rhesus monkeys.Behavioral effects and pharmacokinetics of (±)-3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) after intragastric administration to baboonsThe neuropharmacology of the age-old sedative/hypnotic, ethanolmiR-181a is a negative regulator of GRIA2 in methamphetamine-use disorder.The inhibitory GABA system as a therapeutic target for cognitive symptoms in schizophrenia: investigational agents in the pipeline.Insights into the structure and pharmacology of GABA(A) receptors.Further evaluation of the potential anxiolytic activity of imidazo[1,5-a][1,4]diazepin agents selective for α2/3-containing GABAA receptors.A Comparison of the α2/3/5 Selective Positive Allosteric Modulators L-838,417 and TPA023 in Preclinical Models of Inflammatory and Neuropathic Pain.Duration of treatment and activation of α1-containing GABAA receptors variably affect the level of anxiety and seizure susceptibility after diazepam withdrawal in rats.βCCT, an antagonist selective for α(1)GABA(A) receptors, reverses diazepam withdrawal-induced anxiety in rats.Abuse-related effects of subtype-selective GABAA receptor positive allosteric modulators in an assay of intracranial self-stimulation in rats.Effects of the benzodiazepine GABAA α1-preferring antagonist 3-isopropoxy-β-carboline hydrochloride (3-ISOPBC) on alcohol seeking and self-administration in baboons.Valium without dependence? Individual GABAA receptor subtype contribution toward benzodiazepine addiction, tolerance, and therapeutic effects.
P2860
Q21296639-A22ABC0F-4B61-4D8E-ACF7-3857359DE465Q30421260-87FA4509-E0D8-4588-80F6-48CF4697912AQ30429949-B461B90C-6774-4DCA-9F8B-2D1D01752E8CQ30466591-2DCE7DDA-0D5C-4310-BC0A-1B8900383EBBQ30580823-7DAED932-28CF-4394-9948-2CAC253903C8Q33607409-77CC30CB-A5C4-4ED0-98BF-1EE65643A4C5Q34389218-EF492515-94C1-4190-A7C9-E16C32F0C6ABQ34630587-DF0569E1-6C2C-4B9E-B22B-C6593D055062Q36421449-99BFA092-2B51-46AD-8AB3-EA83F1692861Q36487793-4481BFB4-1171-43ED-9B0A-DCD0F1C3628DQ36533714-3A8E548B-9FA2-4734-AD51-B183D0A84DE4Q36592958-23A7A802-BABA-40E9-A4B1-780650A322C0Q36775238-0A6F14A4-B8C6-427A-95FF-F2E5A053549BQ36852604-A67A7F53-920E-4997-82E0-B9FCABB8EC92Q37011246-B1A7D008-D01B-496D-8E6C-56688EB00169Q37355567-94BCDDA5-3A7C-4567-A729-57FA836EB647Q37784829-53783355-AFC6-4017-8B68-C4F2FEBD65D5Q37855931-BD16C6B5-FBAE-408D-ADAF-A89F59F10992Q38820230-31A57D8D-1B92-45D3-B345-5F87D1B691A1Q39456055-B41D5414-EE4C-4204-83A2-99A53BF9B15CQ40983182-E3C4E96F-54C4-4437-8563-E1811158B6A5Q42044694-A2DA9DA0-5969-40CD-B148-D8B0CF75361FQ45056140-82EF4A3F-A3EE-4730-8225-971E99B75B16Q47383106-E9E0A9B0-4C5A-4AEF-83D4-0BBB3399FD93Q55057714-A4B73D69-B829-419A-80CB-ABAB9E8B10DE
P2860
Reducing abuse liability of GABAA/benzodiazepine ligands via selective partial agonist efficacy at alpha1 and alpha2/3 subtypes.
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Reducing abuse liability of GA ...... alpha1 and alpha2/3 subtypes.
@ast
Reducing abuse liability of GA ...... alpha1 and alpha2/3 subtypes.
@en
Reducing abuse liability of GA ...... alpha1 and alpha2/3 subtypes.
@nl
type
label
Reducing abuse liability of GA ...... alpha1 and alpha2/3 subtypes.
@ast
Reducing abuse liability of GA ...... alpha1 and alpha2/3 subtypes.
@en
Reducing abuse liability of GA ...... alpha1 and alpha2/3 subtypes.
@nl
prefLabel
Reducing abuse liability of GA ...... alpha1 and alpha2/3 subtypes.
@ast
Reducing abuse liability of GA ...... alpha1 and alpha2/3 subtypes.
@en
Reducing abuse liability of GA ...... alpha1 and alpha2/3 subtypes.
@nl
P2093
P2860
P356
P1476
Reducing abuse liability of GA ...... alpha1 and alpha2/3 subtypes.
@en
P2093
Gerard R Dawson
H Donald Burns
Nancy A Ator
Richard J Hargreaves
P2860
P356
10.1124/JPET.109.158303
P407
P50
P577
2009-09-29T00:00:00Z